表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌(NSCLC)有较好疗效,目前临床常用药物为吉非替尼,厄洛替尼和埃克替尼。随着EGFR-TKI在临床的广泛应用,关于其不良反应的研究也不断深入。EGFR-TKI主要不良反应为皮疹、甲沟炎、毛发改变、腹泻、肝脏损害和间质性肺疾病等。引起不良反应的机制大多不明确。对于较常见的皮疹、甲沟炎等不良反应,较轻时可给予对症处理,严重时应减量或停药;对于较严重的肝脏损害或间质性肺疾病,给予对症治疗的同时要定期检测肝、肺功能。 Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment of non-small cell lung cancer (NSCLC) has a good effect, the current clinical drugs gefitinib, erlotinib and icotinib. With the widespread use of EGFR-TKI in clinical practice, the research on its adverse reactions has been deepened. The main adverse reactions of EGFR-TKI were rash, paronychia, hair changes, diarrhea, liver damage and interstitial lung disease. Most of the mechanisms that cause adverse reactions are not clear. For the more common rash, paronychia and other adverse reactions, may be given symptomatic treatment lighter, severe cases should be reduced or discontinued; for more severe liver damage or interstitial lung disease, given symptomatic treatment at the same time to be regularly Detection of liver and lung function.